Martin Auster
Stock Analyst at Raymond James
(0.59)
# 4,286
Out of 4,970 analysts
50
Total ratings
50%
Success rate
-13.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Martin Auster
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DYN Dyne Therapeutics | Upgrades: Strong Buy | $31 → $35 | $13.24 | +164.35% | 2 | Aug 25, 2025 | |
| ALNY Alnylam Pharmaceuticals | Reiterates: Outperform | $370 → $424 | $453.54 | -6.51% | 1 | Aug 1, 2025 | |
| BMRN BioMarin Pharmaceutical | Initiates: Buy | $120 | $56.75 | +111.45% | 7 | Sep 18, 2023 | |
| RARE Ultragenyx Pharmaceutical | Upgrades: Outperform | $99 → $105 | $31.28 | +235.68% | 7 | Mar 16, 2022 | |
| FULC Fulcrum Therapeutics | Initiates: Outperform | $26 | $6.83 | +280.67% | 1 | Mar 22, 2021 | |
| SLDB Solid Biosciences | Maintains: Neutral | $105 → $120 | $5.56 | +2,058.27% | 4 | Mar 16, 2021 | |
| GLTO Galecto | Maintains: Outperform | $725 → $300 | $3.00 | +9,900.00% | 2 | Mar 16, 2021 | |
| STOK Stoke Therapeutics | Maintains: Outperform | $49 → $58 | $19.63 | +195.47% | 3 | Mar 10, 2021 | |
| UTHR United Therapeutics | Maintains: Outperform | $169 → $196 | $380.47 | -48.48% | 4 | Feb 22, 2021 | |
| ALXO ALX Oncology Holdings | Maintains: Outperform | $62 → $98 | $1.08 | +8,974.07% | 2 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $60 | $142.53 | -57.90% | 2 | Jan 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $65 | $32.44 | +100.37% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $156 → $73 | $18.46 | +295.45% | 4 | Jan 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $5.35 | - | 2 | Dec 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $76 → $78 | $17.73 | +339.93% | 1 | Nov 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $2.53 | - | 2 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $43 | $8.13 | +428.91% | 2 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $34 | $48.47 | -29.85% | 1 | Jul 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $21 | $11.62 | +80.72% | 1 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $16 | $21.08 | -24.10% | 1 | May 7, 2020 |
Dyne Therapeutics
Aug 25, 2025
Upgrades: Strong Buy
Price Target: $31 → $35
Current: $13.24
Upside: +164.35%
Alnylam Pharmaceuticals
Aug 1, 2025
Reiterates: Outperform
Price Target: $370 → $424
Current: $453.54
Upside: -6.51%
BioMarin Pharmaceutical
Sep 18, 2023
Initiates: Buy
Price Target: $120
Current: $56.75
Upside: +111.45%
Ultragenyx Pharmaceutical
Mar 16, 2022
Upgrades: Outperform
Price Target: $99 → $105
Current: $31.28
Upside: +235.68%
Fulcrum Therapeutics
Mar 22, 2021
Initiates: Outperform
Price Target: $26
Current: $6.83
Upside: +280.67%
Solid Biosciences
Mar 16, 2021
Maintains: Neutral
Price Target: $105 → $120
Current: $5.56
Upside: +2,058.27%
Galecto
Mar 16, 2021
Maintains: Outperform
Price Target: $725 → $300
Current: $3.00
Upside: +9,900.00%
Stoke Therapeutics
Mar 10, 2021
Maintains: Outperform
Price Target: $49 → $58
Current: $19.63
Upside: +195.47%
United Therapeutics
Feb 22, 2021
Maintains: Outperform
Price Target: $169 → $196
Current: $380.47
Upside: -48.48%
ALX Oncology Holdings
Feb 11, 2021
Maintains: Outperform
Price Target: $62 → $98
Current: $1.08
Upside: +8,974.07%
Jan 19, 2021
Maintains: Outperform
Price Target: $50 → $60
Current: $142.53
Upside: -57.90%
Jan 11, 2021
Initiates: Outperform
Price Target: $65
Current: $32.44
Upside: +100.37%
Jan 8, 2021
Maintains: Neutral
Price Target: $156 → $73
Current: $18.46
Upside: +295.45%
Dec 10, 2020
Downgrades: Underperform
Price Target: n/a
Current: $5.35
Upside: -
Nov 20, 2020
Maintains: Outperform
Price Target: $76 → $78
Current: $17.73
Upside: +339.93%
Nov 10, 2020
Upgrades: Outperform
Price Target: n/a
Current: $2.53
Upside: -
Oct 8, 2020
Maintains: Outperform
Price Target: $27 → $43
Current: $8.13
Upside: +428.91%
Jul 7, 2020
Initiates: Outperform
Price Target: $34
Current: $48.47
Upside: -29.85%
Jun 2, 2020
Maintains: Neutral
Price Target: $19 → $21
Current: $11.62
Upside: +80.72%
May 7, 2020
Maintains: Neutral
Price Target: $14 → $16
Current: $21.08
Upside: -24.10%